Investigations
Teleflex Incorporated
Overview
Overview
- Deadline:
- Upcoming
| Company Name: | Company Name: Teleflex Incorporated |
| Stock Symbol: | Stock Symbol: TFX |
Teleflex Incorporated (NYSE: TFX): Teleflex is being investigated for violations of the federal securities laws in connection with potential false and misleading statements made to investors and a subsequent significant price decline in the stock.
If you incurred losses on your investments in Teleflex, you are encouraged to submit your information.
Why is Teleflex being Investigated?
Teleflex is a global provider of medical technology products used by hospitals and healthcare providers in critical care and surgical applications. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
Given these announcements, BFA is investigating whether Teleflex and certain of its senior officers made materially false and misleading statements to investors given the company’s past positive representations.
The Stock Declines as the Truth is Revealed
As a result of Teleflex’s announcement on February 27, 2025, the company’s stock price declined approximately 20% during trading.
What are my Rights?
If you incurred losses on your investments in Teleflex, you are encouraged to submit your information to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
If you incurred losses on your investments in Teleflex, you are encouraged to submit your information.
Why is Teleflex being Investigated?
Teleflex is a global provider of medical technology products used by hospitals and healthcare providers in critical care and surgical applications. On February 27, 2025 the company announced that it was splitting off its Urology, Acute Care and OEM businesses into a new publicly traded company, the resignation of its CFO, and that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing.
Given these announcements, BFA is investigating whether Teleflex and certain of its senior officers made materially false and misleading statements to investors given the company’s past positive representations.
The Stock Declines as the Truth is Revealed
As a result of Teleflex’s announcement on February 27, 2025, the company’s stock price declined approximately 20% during trading.
What are my Rights?
If you incurred losses on your investments in Teleflex, you are encouraged to submit your information to speak with an attorney about your rights.
You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619
All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.